As the largest pharma and tech suppliers – from Novartis to GE Healthcare to Thermo Fisher – begin exploring the world of CRISPR/Cas gene editing technology, contract research organizations are also looking into the new tech to explore ways to help clients’ research models.
A recent spate of activity - including the acquisition of a Japanese CRO and a secondary equity offering - has boosted Quintiles’ investment appeal, an analyst says.
Following a re-examination requested by MAHs (marketing authorisation holders) for seven of the medicines suspended, the EMA has re-confirmed its recommendation to suspend hundreds of drugs following issues with clinical studies conducted at CRO GVK Biosciences in Hyderabad, India.
In a House bill that largely mirrors one reintroduced earlier this year in the Senate, CROs (contract research organizations) would be able to capture a share of the R&D tax credit, thereby making the US more competitive with other countries that offer such credits.
A consortium including WuXi PharmaTech has agreed to acquire biotech client Ambrx for its antibody-drug conjugate (ADC) conjugation technology.
inVentiv Health has expanded its compliance products and services to assist biopharma companies conducting non-interventional studies (NIS).